Fresenius Kabi to acquire Ivenix and its smart infusion system for $240M upfront
Summary
The acquisition, which has a purchase price of $240 million upfront, also includes potential milestone payments linked to achievements of commercial and operating targets. Fresenius Kabi plans to build on the acquisition by accelerating operational and commercial growth and scale to create a platform for rapid expansion and establish itself as a leader in the growing infusion market. “We’re very pleased to partner with Fresenius Kabi, a leading global health care company,” Ivenix CEO Jorgen B. Hansen said in the release. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity,” Fresenius Kabi President and CEO Michael Sen said. “We will continue allocating capital in a targeted manner to rigorously pursue the recently presented growth strategy of our health care group which has defined Fresenius Kabi as top priority.
Classifications
AskAI Classifications
LabelsLinked Companies
